Activated protein C and its potential applications in prevention of islet β-cell damage and diabetes

Vitamins and Hormones

Volumn 95, Issue , 2014, Pages 323-363

  Xue, Meilang ^a   Jackson, Christopher J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Activated protein C; Apoptosis; Diabetes; Endothelial protein C receptor; Islet cells

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PROTECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ADVERSE EFFECTS; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, TYPE 1; ENZYME ACTIVATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MODELS, BIOLOGICAL; PROTECTIVE AGENTS; PROTEIN C; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84894037713     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800174-5.00013-2     Document Type: Chapter

References (219)

1. Ablamunits V., Sherry N.A., Kushner J.A., Herold K.C. Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: The peace is not enough. Annals of the New York Academy of Sciences 2007, 1103:19-32.
2. Adorini L., Gregori S., Harrison L.C. Understanding autoimmune diabetes: Insights from mouse models. Trends in Molecular Medicine 2002, 8:31-38.
3. Akima S., Hawthorne W.J., Favaloro E., Patel A., Blyth K., Mudaliar Y., et al. Tirofiban and activated protein C synergistically inhibit the instant blood mediated inflammatory reaction (IBMIR) from allogeneic islet cells exposure to human blood. American Journal of Transplantation 2009, 9:1533-1540.
4. Anstee Q.M., Dhar A., Thursz M.R. The role of hypercoagulability in liver fibrogenesis. Clinics and Research in Hepatology and Gastroenterology 2011, 35:526-533.
5. Anthony D.A., Andrews D.M., Watt S.V., Trapani J.A., Smyth M.J. Functional dissection of the granzyme family: Cell death and inflammation. Immunological Reviews 2010, 235:73-92.
6. Bae J.S., Lee W., Rezaie A.R. Polyphosphate elicits pro-inflammatory responses that are counteracted by activated protein C in both cellular and animal models. Journal of Thrombosis and Haemostasis 2012, 10:1145-1151.
7. Bae J.S., Yang L., Manithody C., Rezaie A.R. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007, 110:3909-3916.
8. Baiu D., Merriam F., Odorico J. Potential pathways to restore beta-cell mass: Pluripotent stem cells, reprogramming, and endogenous regeneration. Current Diabetes Reports 2011, 11:392-401.
9. Baker W.F., Bick R.L. Treatment of hereditary and acquired thrombophilic disorders. Seminars in Thrombosis and Hemostasis 1999, 25:387-406.
10. Balazs A.B., Fabian A.J., Esmon C.T., Mulligan R.C. Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow. Blood 2006, 107:2317-2321.
11. Bartolome S., Wood J.G., Casillan A.J., Simpson S.Q., O'brien-Ladner A.R. Activated protein C attenuates microvascular injury during systemic hypoxia. Shock 2008, 29:384-387.
12. Bending D., Zaccone P., Cooke A. Inflammation and type one diabetes. International Immunology 2012, 24:339-346.
13. Bensellam M., Laybutt D.R., Jonas J.C. The molecular mechanisms of pancreatic beta-cell glucotoxicity: Recent findings and future research directions. Molecular and Cellular Endocrinology 2012, 364:1-27.
14. Bertina R.M., Broekmans A.W., Van Der Linden I.K., Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thrombosis and Hemostasis 1982, 48:1-5.
15. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
16. Bettini M., Vignali D.A. T cell-driven initiation and propagation of autoimmune diabetes. Current Opinion in Immunology 2011, 23:754-760.
17. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
18. Bock F., Shahzad K., Wang H., Stoyanov S., Wolter J., Dong W., et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:648-653.
19. Bosco D., Armanet M., Morel P., Niclauss N., Sgroi A., Muller Y.D., et al. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes 2010, 59:1202-1210.
20. Bouwens E.A., Mosnier L.O. EPCR encryption induces cellular APC resistance. Blood 2012, 119:2703-2705.
21. Bretschneider E., Uzonyi B., Weber A.A., Fischer J.W., Pape R., Lotzer K., et al. Human vascular smooth muscle cells express functionally active endothelial cell protein C receptor. Circulation Research 2007, 100:255-262.
22. Brissova M., Fowler M.J., Nicholson W.E., Chu A., Hirshberg B., Harlan D.M., et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. The Journal of Histochemistry and Cytochemistry 2005, 53:1087-1097.
23. Brunner T., Wasem C., Torgler R., Cima I., Jakob S., Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Seminars in Immunology 2003, 15:167-176.
24. Buisson-Legendre N., Smith S., March L., Jackson C. Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis and Rheumatism 2004, 50:2151-2156.
25. Cabrera O., Berman D.M., Kenyon N.S., Ricordi C., Berggren P.O., Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2334-2339.
26. Cai D. One step from prediabetes to diabetes: Hypothalamic inflammation?. Endocrinology 2012, 153:1010-1013.
27. Calzado M.A., Bacher S., Schmitz M.L. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Current Medicinal Chemistry 2007, 14:367-376.
28. Campbell P.D., Estella E., Dudek N.L., Jhala G., Thomas H.E., Kay T.W., et al. Cytotoxic T-lymphocyte-mediated killing of human pancreatic islet cells in vitro. Human Immunology 2008, 69:543-551.
29. Cao C., Gao Y., Li Y., Antalis T.M., Castellino F.J., Zhang L. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. The Journal of Clinical Investigation 2010, 120:1971-1980.
30. Castoldi E., Rosing J. APC resistance: Biological basis and acquired influences. Journal of Thrombosis and Haemostasis 2010, 8:445-453.
31. Chalmers E., Cooper P., Forman K., Grimley C., Khair K., Minford A., et al. Purpura fulminans: Recognition, diagnosis and management. Archives of Disease in Childhood 2011, 96:1066-1071.
32. Cheng T., Liu D., Griffin J.H., Fernandez J.A., Castellino F., Rosen E.D., et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Medicine 2003, 9:338-342.
33. Cheng T., Petraglia A.L., Li Z., Thiyagarajan M., Zhong Z., Wu Z., et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nature Medicine 2006, 12:1278-1285.
34. Christianson S.W., Shultz L.D., Leiter E.H. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993, 42:44-55.
35. Cnop M., Welsh N., Jonas J.C., Jorns A., Lenzen S., Eizirik D.L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Diabetes 2005, 54(Suppl. 2):S97-S107.
36. Contreras J.L., Eckstein C., Smyth C.A., Bilbao G., Vilatoba M., Ringland S.E., et al. Activated protein C preserves functional islet mass after intraportal transplantation: A novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004, 53:2804-2814.
37. Coppieters K.T., Dotta F., Amirian N., Campbell P.D., Kay T.W., Atkinson M.A., et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. Journal of Experimental Medicine 2012, 209:51-60.
38. Cornet A.D., Hofstra J.J., Vlaar A.P., Tuinman P.R., Levi M., Girbes A.R., et al. Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis 2013, 11:894-901.
39. Cory S., Adams J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nature Reviews. Cancer 2002, 2:647-656.
40. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
41. Cui W., Wilson J.T., Wen J., Angsana J., Qu Z., Haller C.A., et al. Thrombomodulin improves early outcomes after intraportal islet transplantation. American Journal of Transplantation 2009, 9:1308-1316.
42. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008, 112:19-27.
43. D'alessio S., Genua M., Vetrano S. The protein C pathway in intestinal barrier function: Challenging the hemostasis paradigm. Annals of the New York Academy of Sciences 2012, 1258:78-85.
44. Degterev A., Boyce M., Yuan J. A decade of caspases. Oncogene 2003, 22:8543-8567.
45. Delovitch T.L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD. Immunity 1997, 7:727-738.
46. Dominguez-Bendala J., Inverardi L., Ricordi C. Regeneration of pancreatic beta-cell mass for the treatment of diabetes. Expert Opinion on Biological Therapy 2012, 12:731-741.
47. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nature Review Immunology 2011, 11:98-107.
48. Du Z.J., Yamamoto T., Ueda T., Suzuki M., Tano Y., Kamei M. Activated protein C rescues the retina from ischemia-induced cell death. Investigative Ophthalmology & Visual Science 2011, 52:987-993.
49. Eizirik D.L., Colli M.L., Ortis F. The role of inflammation in insulitis and [beta]-cell loss in type 1 diabetes. Nature Reviews. Endocrinology 2009, 5:219-226.
50. Elayat A.A., El-Naggar M.M., Tahir M. An immunocytochemical and morphometric study of the rat pancreatic islets. Journal of Anatomy 1995, 186(Pt 3):629-637.
51. Eldor R., Yeffet A., Baum K., Doviner V., Amar D., Ben-Neriah Y., et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5072-5077.
52. Elphick G.F., Sarangi P.P., Hyun Y.M., Hollenbaugh J.A., Ayala A., Biffl W.L., et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009, 113:4078-4085.
53. Esmon C.T. Crosstalk between inflammation and thrombosis. Maturitas 2004, 47:305-314.
54. Esmon C.T. Structure and functions of the endothelial cell protein C receptor. Critical Care Medicine 2004, 32:S298-S301.
55. Esmon C.T. Protein C anticoagulant system-Anti-inflammatory effects. Seminars in Immunopathology 2012, 34:127-132.
56. Esmon C.T., Stenflo J., Suttie J.W. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. Journal of Biological Chemistry 1976, 251:3052-3056.
57. Favaloro B., Allocati N., Graziano V., Di Ilio C., De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY) 2012, 4:330-349.
58. Feistritzer C., Mosheimer B.A., Sturn D.H., Riewald M., Patsch J.R., Wiedermann C.J. Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. Journal of Immunology 2006, 176:1019-1025.
59. Feistritzer C., Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005, 105:3178-3184.
60. Feistritzer C., Schuepbach R.A., Mosnier L.O., Bush L.A., Di C.E., Griffin J.H., et al. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. Journal of Biological Chemistry 2006, 281:20077-20084.
61. Finigan J.H., Dudek S.M., Singleton P.A., Chiang E.T., Jacobson J.R., Camp S.M., et al. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. Journal of Biological Chemistry 2005, 280:17286-17293.
62. Foster D.C., Yoshitake S., Davie E.W. The nucleotide sequence of the gene for human protein C. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:4673-4677.
63. Franscini N., Bachli E.B., Blau N., Leikauf M.S., Schaffner A., Schoedon G. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 2004, 110:2903-2909.
64. Frommhold D., Tschada J., Braach N., Buschmann K., Doerner A., Pflaum J., et al. Protein C concentrate controls leukocyte recruitment during inflammation and improves survival during endotoxemia after efficient in vivo activation. American Journal of Pathology 2011, 179:2637-2650.
65. Fukudome K., Esmon C.T. Identification, cloning, and regulation of a novel endothelial cell protein c activated protein c receptor. Journal of Biological Chemistry 1994, 269:26486-26491.
66. Fukuhara S., Sako K., Minami T., Noda K., Kim H.Z., Kodama T., et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nature Cell Biology 2008, 10:513-526.
67. Funk D.J., Palma Vargas J., Tuttle-Newhall J., Moretti E.W. The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: Case series and review of the literature. Transplant Infectious Disease 2011, 13:592-597.
68. Furuse M., Hata M., Furuse K., Yoshida Y., Haratake A., Sugitani Y., et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice. Journal of Cell Biology 2002, 156:1099-1111.
69. Galley H.F., El Sakka N.E., Webster N.R., Lowes D.A., Cuthbertson B.H. Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. British Journal of Anaesthesia 2008, 100:815-819.
70. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370:555-557.
71. Goldenberg N.A., Manco-Johnson M.J. Protein C deficiency. Haemophilia 2008, 14:1214-1221.
72. Gramling M.W., Beaulieu L.M., Church F.C. Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Experimental Cell Research 2010, 316:314-328.
73. Green E.A., Gorelik L., Mcgregor C.M., Tran E.H., Flavell R.A. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10878-10883.
74. Grey S.T., Tsuchida A., Hau H., Orthner C.L., Salem H.H., Hancock W.W. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. Journal of Immunology 1994, 153:3664-3672.
75. Griffin, J. H. (2002). Stabilization of protein complexes by introduction cysteine residues and the formation of disulfide bonds (p. 98), Vol. 2002-US19017. Patent Number: 2002103024. US.
76. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease. The Journal of Clinical Investigation 1981, 68:1370-1373.
77. Gruber A., Griffin J.H. Direct detection of activated protein C in blood from human subjects. Blood 1992, 79:2340-2348.
78. Gruber B.L., Sorbi D., French D.L., Marchese R.R.J., Nuovo G.J., Kew R.R., et al. Markedly elevated serum mmp-9 (gelatinase b) levels in rheumatoid arthritis-A potentially useful laboratory marker. Clinical Immunology and Immunopathology 1996, 78:161-171.
79. Gruden G., Olivetti C., Cavallo-Perin P., Bazzan M., Stella S., Tamponi G., et al. Activated protein C resistance in type I diabetes. Diabetes Care 1997, 20:424-425.
80. Gu J.M., Crawley J.T.B., Ferrell G., Zhang F., Li W., Esmon N.L., et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. Journal of Biological Chemistry 2002, 277:43335-43343.
81. Guo H., Liu D., Gelbard H., Cheng T., Insalaco R., Fernandez J.A., et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004, 41:563-572.
82. Guo H., Zhao Z., Yang Q., Wang M., Bell R.D., Wang S., et al. An activated protein C snalog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. Journal of Neuroscience 2013, 33:6181-6190.
83. Hansen T.M., Singh H., Tahir T.A., Brindle N.P. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cellular Signalling 2010, 22:527-532.
84. Harris R.J., Cropley T.G. Possible role of hypercoagulability in calciphylaxis: Review of the literature. Journal of the American Academy of Dermatology 2011, 64:405-412.
85. Hemmer C.J., Lobermann M., Unverricht M., Vogt A., Krause R., Reisinger E.C. Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis. Tropical Medicine & International Health 2011, 16:906-913.
86. Hotchkiss R.S., Chang K.C., Swanson P.E., Tinsley K.W., Hui J.J., Klender P., et al. Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte. Nature Immunology 2000, 1:496-501.
87. Hudson L.G., Mccawley L.J. Contributions of the epidermal growth factor receptor to keratinocyte motility. Microscopy Research and Technique 1998, 43:444-455.
88. Isermann B., Vinnikov I.A., Madhusudhan T., Herzog S., Kashif M., Blautzik J., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nature Medicine 2007, 13:1349-1358.
89. Isobe H., Okajima K., Harada N., Liu W., Okabe H. Activated protein C reduces stress-induced gastric mucosal injury in rats by inhibiting the endothelial cell injury. Journal of Thrombosis and Haemostasis 2004, 2:313-320.
90. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. Journal of Immunology 2002, 169:2643-2647.
91. Jackson C.J., Xue M., Thompson P., Davey R.A., Whitmont K., Smith S., et al. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair and Regeneration 2005, 13:284-294.
92. Jaffre F., Friedman A.E., Hu Z., Mackman N., Blaxall B.C. Beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation 2012, 125:2993-3003.
93. Jalbert L.R., Rosen E.D., Moons L., Chan J.C., Carmeliet P., Collen D., et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. Journal of Clininal Investigation 1998, 102:1481-1488.
94. Johnson J.D., Luciani D.S. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Advances in Experimental Medicine and Biology 2010, 654:447-462.
95. Joyce D.E., Gelbert L., Ciaccia A., Dehoff B., Grinnell B.W. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. Journal of Biological Chemistry 2001, 276:11199-11203.
96. Joyce D.E., Grinnell B.W. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Critical Care Medicine 2002, 30:S288-S293.
97. Julovi S.M., Xue M., Dervish S., Sambrook P.N., March L., Jackson C.J. Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38. American Journal of Pathology 2011, 179:2233-2242.
98. Keller S.A., Moore C.C., Evans S.L., Mckillop I.H., Huynh T. Activated protein C alters inflammation and protects renal function in sepsis. Journal of Surgical Research 2011, 168:e103-e109.
99. Kerschen E.J., Fernandez J.A., Cooley B.C., Yang X.V., Sood R., Mosnier L.O., et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. Journal of Experimental Medicine 2007, 204:2439-2448.
100. Kerschen E., Hernandez I., Zogg M., Jia S., Hessner M.J., Fernandez J.A., et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. The Journal of Clinical Investigation 2010, 120:3167-3178.
101. Kim K.A., Lee M.S. Recent progress in research on beta-cell apoptosis by cytokines. Frontiers in Bioscience 2009, 14:657-664.
102. Kirschner N., Brandner J.M. Barriers and more: Functions of tight junction proteins in the skin. Annals of the New York Academy of Sciences 2012, 1257:158-166.
103. Kohnert K.D., Freyse E.J., Salzsieder E. Glycaemic variability and pancreatic beta-cell dysfunction. Current Diabetes Reviews 2012, 8:345-354.
104. Koster M.I. Making an epidermis. Annals of the New York Academy of Sciences 2009, 1170:7-10.
105. Kumar S. Caspase function in programmed cell death. Cell Death and Differentiation 2007, 14:32-43.
106. Kurata T., Hayashi T., Yoshikawa T., Okamoto T., Yoshida K., Iino T., et al. Activated protein C stimulates osteoblast proliferation via endothelial protein C receptor. Thrombosis Research 2010, 125:184-191.
107. Lay A.J., Donahue D., Tsai M.J., Castellino F.J. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007, 109:1984-1991.
108. Lay A.J., Liang Z., Rosen E.D., Castellino F.J. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. The Journal of Clinical Investigation 2005, 115:1552-1561.
109. Leger A.J., Covic L., Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006, 114:1070-1077.
110. Lehmann C., Scheibe R., Schade M., Meissner K., Grundling M., Usichenko T., et al. Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia. Canadian Journal of Anesthesia 2008, 55:155-162.
111. Levi M., Dorffler-Melly J., Reitsma P., Buller H., Florquin S., Van Der Poll T., et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 2003, 101:4823-4827.
112. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nature Reviews. Immunology 2002, 2:725-734.
113. Li W., Zheng X., Gu J.M., Ferrell G.L., Brady M., Esmon N.L., et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005, 106:2716-2722.
114. Li W., Zheng X., Gu J., Hunter J., Ferrell G.L., Lupu F., et al. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. Journal of Thrombosis and Haemostasis 2005, 3:1351-1359.
115. Liaw P.C., Esmon C.T., Kahnamoui K., Schmidt S., Kahnamoui S., Ferrell G., et al. Patients with severe sepsis vary markedly in their ability to generate activate protein C. Blood 2004, 104:3958-3964.
116. Lightfoot Y.L., Chen J., Mathews C.E. Role of the mitochondria in immune-mediated apoptotic death of the human pancreatic beta cell line betaLox5. PLoS One 2011, 6:e20617.
117. Liu D., Cheng T., Guo H., Fernandez J.A., Griffin J.H., Song X., et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nature Medicine 2004, 10:1379-1383.
118. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001, 104:487-501.
119. Madhusudhan T., Wang H., Straub B.K., Grone E., Zhou Q., Shahzad K., et al. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 2012, 119:874-883.
120. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. American Journal of Pathology 1995, 146:3-15.
121. Makinde T., Agrawal D.K. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. Journal of Cellular and Molecular Medicine 2008, 12:810-828.
122. Marchiando A.M., Graham W.V., Turner J.R. Epithelial barriers in homeostasis and disease. Annual Review of Pathology 2010, 5:119-144.
123. Mcquibban G.A., Gong J.H., Tam E.M., Mcculloch C.A., Clark-Lewis I., Overall C.M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000, 289:1202-1206.
124. Mcquibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002, 100:1160-1167.
125. Melloul D. Role of NF-kappaB in beta-cell death. Biochemical Society Transactions 2008, 36:334-339.
126. Minhas N., Xue M., Fukudome K., Jackson C.J. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB Journal 2010, 24:873-881.
127. Mizutani A., Okajima K., Uchiba M., Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000, 95:3781-3787.
128. Mosnier L.O., Griffin J.H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochemical Journal 2003, 373:65-70.
129. Mosnier L.O., Sinha R.K., Burnier L., Bouwens E.A., Griffin J.H. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 2012, 120:5237-5246.
130. Mosnier L.O., Yang X.V., Griffin J.H. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. Journal of Biological Chemistry 2007, 282:33022-33033.
131. Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H., et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. American Journal of Physiology 1997, 272:L197-L202.
132. Nagai M., Yilmaz C.E., Kirchhofer D., Esmon C.T., Mackman N., Granger D.N. Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis. Neurosurgery 2010, 66:560-565. discussion 565-566.
133. Nakajima H., Park H.L., Henkart P.A. Synergistic roles of granzymes A and B in mediating target cell death by rat basophilic leukemia mast cell tumors also expressing cytolysin/perforin. Journal of Experimental Medicine 1995, 181:1037-1046.
134. Nguyen M., Arkell J., Jackson C.J. Activated protein C directly activates human endothelial gelatinase A. Journal of Biological Chemistry 2000, 275:9095-9098.
135. Nick J.A., Coldren C.D., Geraci M.W., Poch K.R., Fouty B.W., O'brien J., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004, 104:3878-3885.
136. Norbury C.J., Hickson I.D. Cellular responses to DNA damage. Annual Review of Pharmacology and Toxicology 2001, 41:367-401.
137. Ochs H.D., Ziegler S.F., Torgerson T.R. FOXP3 acts as a rheostat of the immune response. Immunology Review 2005, 203:156-164.
138. Okajima K. Regulation of inflammatory responses by activated protein C: The molecular mechanism(s) and therapeutic implications. Clinical Chemistry and Laboratory Medicine 2004, 42:132-141.
139. Ortis F., Pirot P., Naamane N., Kreins A.Y., Rasschaert J., Moore F., et al. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008, 51:1213-1225.
140. Park S.Y., Lee H.E., Li H., Shipitsin M., Gelman R., Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clinical Cancer Research 2010, 16:876-887.
141. Pereira C., Schaer D.J., Bachli E.B., Kurrer M.O., Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:504-510.
142. Peters K.G. Functional significance of Tie2 signaling in the adult vasculature. Recent Progress in Hormone Research 2004, 59:51-71.
143. Petraglia A.L., Marky A.H., Walker C., Thiyagarajan M., Zlokovic B.V. Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact. Neurosurgery 2010, 66:165-171.
144. Pina-Canseco Mdel S., Paez-Arenas A., Masso F., Perez-Campos E., Martinez-Cruz R., Hernandez-Cruz P., et al. Protein C activation peptide inhibits the expression of ICAM-1, VCAM-1, and interleukin-8 induced by TNF-alpha in human dermal microvascular endothelial cells. Folia Histochemica et Cytobiologica 2012, 50:407-413.
145. Plutzky J., Hoskins J.A., Long G.L., Crabtree G.R. Evolution and organization of the human protein C gene. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:546-550.
146. Price V.E., Ledingham D.L., Krumpel A., Chan A.K. Diagnosis and management of neonatal purpura fulminans. Seminars in Fetal & Neonatal Medicine 2011, 16:318-322.
147. Proksch E., Brandner J.M., Jensen J.M. The skin: An indispensable barrier. Experimental Dermatology 2008, 17:1063-1072.
148. Proksch E., Brasch J. Abnormal epidermal barrier in the pathogenesis of contact dermatitis. Clinical Dermatology 2012, 30:335-344.
149. Proskuryakov S.Y., Konoplyannikov A.G., Gabai V.L. Necrosis: A specific form of programmed cell death?. Experimental Cell Research 2003, 283:1-16.
150. Puig F., Fuster G., Adda M., Blanch L., Farre R., Navajas D., et al. Barrier-protective effects of activated protein C in human alveolar epithelial cells. PLoS One 2013, 8:e56965.
151. Ram M., Sherer Y., Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. Journal of Clinical Immunology 2006, 26:299-307.
152. Riewald M., Petrovan R.J., Donner A., Mueller B.M., Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002, 296:1880-1882.
153. Roglic G., Unwin N. Mortality attributable to diabetes: Estimates for the year 2010. Diabetes Research and Clinical Practice 2010, 87:15-19.
154. Saelens X., Festjens N., Vande Walle L., Van Gurp M., Van Loo G., Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23:2861-2874.
155. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
156. Sakar A., Vatansever S., Sepit L., Ozbilgin K., Yorgancioglu A. Effect of recombinant human activated protein C on apoptosis-related proteins. European Journal of Histochemistry 2007, 51:103-109.
157. Salem H.H., Broze G.J., Miletich J.P., Majerus P.W. Human coagulation factor Va is a cofactor for the activation of protein C. Proceedings of the National Academy of Sciences of the United States of America 1983, 80:1584-1588.
158. Salmon A.H.J., Neal C.R., Sage L.M., Glass C.A., Harper S.J., Bates D.O. Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovascular Research 2009, 83:24-33.
159. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
160. Sasi N., Hwang M., Jaboin J., Csiki I., Lu B. Regulated cell death pathways: New twists in modulation of BCL2 family function. Molecular Cancer Therapeutics 2009, 8:1421-1429.
161. Sattar N. Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabetic Medicine 2012, 29:5-13.
162. Seol J.W., Lee Y.J., Jackson C.J., Sambrook P.N., Park S.Y. Activated protein C inhibits bisphosphonate-induced endothelial cell death via the endothelial protein C receptor and nuclear factor-kappaB pathways. International Journal of Molecular Medicine 2011, 27:835-840.
163. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010, 87:4-14.
164. Shibata M., Kumar S.R., Amar A., Fernandez J.A., Hofman F., Griffin J.H., et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001, 103:1799-1805.
165. Slee E.A., Adrain C., Martin S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. Journal of Biological Chemistry 2001, 276:7320-7326.
166. Slofstra S.H., Groot A.P., Maris N.A., Reitsma P.H., Cate H.T., Spek C.A. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. British Journal of Pharmacology 2006, 149:740-746.
167. Soh U.J., Dores M.R., Chen B., Trejo J. Signal transduction by protease-activated receptors. British Journal of Pharmacology 2010, 160:191-203.
168. Soh U.J., Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:E1372-E1380.
169. Stearns-Kurosawa D.J., Kurosawa S., Mollica J.S., Ferrell G.L., Esmon C.T. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:10212-10216.
170. Stephenson D.A., Toltl L.J., Beaudin S., Liaw P.C. Modulation of monocyte function by activated protein C, a natural anticoagulant. The Journal of Immunology 2006, 177:2115-2122.
171. Sugiura M. Pregnancy and delivery in protein C-deficiency. Current Drug Targets 2005, 6:577-583.
172. Tait S.W., Green D.R. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nature Reviews. Molecular Cell Biology 2010, 11:621-632.
173. Tait R.C., Walker I.D., Reitsma P.H., Islam S.I., Mccall F., Poort S.R., et al. Prevalence of protein C deficiency in the healthy population. Thrombosis and Haemostasis 1995, 73:87-93.
174. Tanaka A., Minoguchi K., Chen X., Oda N., Yokoe T., Yamamoto Y., et al. Activated protein C attenuates leukocyte elastase-induced lung injury in mice. Shock 2008, 30:153-158.
175. Taylor F.B., Chang A., Esmon C.T., D'angelo A., Vigano-D'angelo S., Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. The Journal of Clinical Investigation 1987, 79:918-925.
176. Taylor F.B., Peer G.T., Lockhart M.S., Ferrell G., Esmon C.T. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001, 97:1685-1688.
177. Taylor F.B., Stearns-Kurosawa D.J., Kurosawa S., Ferrell G., Chang A.C., Laszik Z., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000, 95:1680-1686.
178. Thiyagarajan M., Fernandez J.A., Lane S.M., Griffin J.H., Zlokovic B.V. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. Journal of Neuroscience 2008, 28:12788-12797.
179. Toltl L.J., Austin R.C., Liaw P.C. Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. Journal of Thrombosis and Haemostasis 2011, 9:582-592.
180. Toltl L.J., Beaudin S., Liaw P.C. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. Journal of Immunology 2008, 181:2165-2173.
181. Trejo J. Protease-activated receptors: New concepts in regulation of G protein-coupled receptor signaling and trafficking. Journal of Pharmacology and Experimental Therapeutics 2003, 307:437-442.
182. Trivedi V., Boire A., Tchernychev B., Kaneider N.C., Leger A.J., O'callaghan K., et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009, 137:332-343.
183. Uchiba M., Okajima K., Oike Y., Ito Y., Fukudome K., Isobe H., et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circulation Research 2004, 95:34-41.
184. Van Sluis G.L., Niers T.M., Esmon C.T., Tigchelaar W., Richel D.J., Buller H.R., et al. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 2009, 114:1968-1973.
185. Van Zonneveld A.J., De Boer H.C., Van Der Veer E.P., Rabelink T.J. Inflammation, vascular injury and repair in rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69:i57-i60.
186. Vandenbroucke E., Mehta D., Minshall R., Malik A.B. Regulation of endothelial junctional permeability. Annals of the New York Academy of Sciences 2008, 1123:134-145.
187. Velthuis J.H., Unger W.W., Abreu J.R., Duinkerken G., Franken K., Peakman M., et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
188. Vetrano S., Ploplis V.A., Sala E., Sandoval-Cooper M., Donahue D.L., Correale C., et al. Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:19830-19835.
189. Vig S., Chitolie A., Sleight S., Bevan D., Dormandy J., Thompson M.M., et al. Prevalence and risk of thrombophilia defects in vascular patients. European Journal of Vascular and Endovascular Surgery 2004, 28:124-131.
190. Villasenor A., Cleaver O. Crosstalk between the developing pancreas and its blood vessels: An evolving dialog. Seminars in Cell and Developmental Biology 2012, 23:685-692.
191. Voskoboinik I., Dunstone M.A., Baran K., Whisstock J.C., Trapani J.A. Perforin: Structure, function, and role in human immunopathology. Immunology Review 2010, 235:35-54.
192. Vukovich T.C., Schernthaner G. Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. Diabetes 1986, 35:617-619.
193. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocrine Reviews 2007, 28:187-218.
194. Wang J., Yang L., Rezaie A.R., Li J. Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. Journal of Thrombosis and Haemostasis 2011, 9:1308-1317.
195. Weijer S., Wieland C.W., Florquin S., Van Der Poll T. A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis. Blood 2005, 106:2761-2768.
196. White T.C., Berny M.A., Tucker E.I., Urbanus R.T., De Groot P.G., Fernandez J.A., et al. Protein C supports platelet binding and activation under flow: Role of glycoprotein Ib and apolipoprotein E receptor 2. Journal of Thrombosis and Haemostasis 2008, 6:995-1002.
197. White B., Schmidt M., Murphy C., Livingstone W., O'toole D., Lawler M., et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. British Journal of Haematology 2000, 110:130-134.
198. Whitmont K., Reid I., Tritton S., March L., Xue M., Lee M., et al. Treatment of chronic leg ulcers with topical activated protein C. Archives of Dermatology 2008, 144:1479-1483.
199. Wijewardena A., Vandervord E., Lajevardi S.S., Vandervord J., Jackson C.J. Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. The International Journal of Lower Extremity Wounds 2011, 10:146-151.
200. Williams P.D., Zlokovic B.V., Griffin J.H., Pryor K.E., Davis T.P. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Current Pharmaceutical Design 2012, 18:4215-4222.
201. Wilson J.T., Haller C.A., Qu Z., Cui W., Urlam M.K., Chaikof E.L. Biomolecular surface engineering of pancreatic islets with thrombomodulin. Acta Biomaterialia 2010, 6:1895-1903.
202. Wu J., Zhou Z., Ye S., Dai H., Ma L., Xu X., et al. Detection of soluble endothelial protein C receptor (sEPCR) in patients with CHD, DM and SLE. Zhonghua Xue Ye Xue Za Zhi 2000, 21:472-474.
203. Xu J., Ji Y., Zhang X., Drake M., Esmon C.T. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. Journal of Thrombosis and Haemostasis 2009, 7:851-856.
204. Xu P., Wu Y., Zhu Y., Dagne G., Johnson G., Cuthbertson D., et al. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care 2010, 33:2508-2513.
205. Xue M., Campbell D., Jackson C.J. Protein C is an autocrine growth factor for human skin keratinocytes. Journal of Biological Chemistry 2007, 282:13610-13616.
206. Xue M., Campbell D., Sambrook P.N., Fukudome K., Jackson C.J. Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. Journal of Investigative Dermatology 2005, 125:1279-1285.
207. Xue M., Chow S.O., Dervish S., Chan Y.K., Julovi S.M., Jackson C.J. Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epidermal growth factor receptor and Tie2. Journal of Biological Chemistry 2011, 286:6742-6750.
208. Xue M., Dervish S., Harrison L.C., Fulcher G., Jackson C.J. Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells and prevents diabetes in NOD mice. Journal of Biological Chemistry 2012, 287:16356-16364.
209. Xue M., March L., Sambrook P.N., Fukudome F., Jackson C.J. Endothelial protein C receptor is over-expressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes. Annals of the Rheumatic Diseases 2007, 66:1574-1580.
210. Xue M., March L., Sambrook P.N., Jackson C.J. Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: Relevance to inflammation in rheumatoid arthritis. Arthritis Rheumtism 2007, 56:2864-2874.
211. Xue M., Minhas N., Chow S.O., Dervish S., Sambrook P.N., March L., et al. Endogenous protein C is essential for the functional integrity of human endothelial cells. Cellular and Molecular Life Sciences 2010, 67:1537-1546.
212. Xue M., Smith M.M., Little C.B., Sambrook P., March L., Jackson C.J. Activated protein C mediates a healing phenotype in cultured tenocytes. Journal of Cellular and Molecular Medicine 2009, 13:749-757.
213. Xue M., Thompson P., Kelso I., Jackson C. Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. Experimental Cell Research 2004, 299:119-127.
214. Yang X.V., Banerjee Y., Fernandez J.A., Deguchi H., Xu X., Mosnier L.O., et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:274-279.
215. Yen Y.T., Yang H.R., Lo H.C., Hsieh Y.C., Tsai S.C., Hong C.W., et al. Enhancing autophagy with activated protein C and rapamycin protects against sepsis-induced acute lung injury. Surgery 2013, 153:689-698.
216. Yuksel M., Okajima K., Uchiba M., Horiuchi S., Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thrombosis and Haemostasis 2002, 88:267-273.
217. Zanone M.M., Favaro E., Camussi G. From endothelial to beta cells: Insights into pancreatic islet microendothelium. Current Diabetes Reviews 2008, 4:1-9.
218. Zhou F. Expression of multiple granzymes by cytotoxic T lymphocyte implies that they activate diverse apoptotic pathways in target cells. International Reviews of Immunology 2010, 29:38-55.
219. Ziegler A.G., Nepom G.T. Prediction and pathogenesis in type 1 diabetes. Immunity 2010, 32:468-478.